Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
24,878
Total Claims
$2.2M
Drug Cost
582
Beneficiaries
$3,726
Cost/Patient
Risk Score Breakdown 21/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+291%
Opioid rate vs peers
10.1% vs 2.6% avg
+249%
Cost per patient vs peers
$3,726 vs $1,068 avg
+11%
Brand preference vs peers
10.0% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Opioid rate is 291% above Family Practice peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
10.1%
Opioid Rate
2,507
Opioid Claims
$82K
Opioid Cost
1.4%
Long-Acting Rate
Brand vs Generic
Brand: 2,460 claims · $1.6M
Generic: 22,232 claims · $527K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 215 | $209K |
| Semaglutide | 129 | $156K |
| Apixaban | 168 | $145K |
| Dulaglutide | 74 | $113K |
| Linaclotide | 96 | $75K |
| Dapagliflozin Propanediol | 66 | $65K |
| Liraglutide | 22 | $62K |
| Insulin Degludec | 57 | $58K |
| Fluticasone/Umeclidin/Vilanter | 49 | $57K |
| Budesonide/Formoterol Fumarate | 83 | $53K |
| Hydrocodone/Acetaminophen | 1,483 | $46K |
| Insulin Glargine,hum.Rec.Anlog | 53 | $43K |
| Sacubitril/Valsartan | 48 | $39K |
| Rivaroxaban | 42 | $39K |
| Insulin Aspart Prot/Insuln Asp | 12 | $34K |
Prescribing Profile
Patient Profile
70
Avg Age
67%
Female
1.55
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data